Patients undergoing CRTcetuximab within the SCOPE-@ trial ( @ patients from @ UK centres ) completed generic - , disease - and treatment-specific health-related quality of life ( HRQL ) questionnaires ( EORTC QLQ-C@ , QLQ-OES@ , Dermatology Life-Quality Index ( DLQI ) ) at baseline and at @ , @ , @ , @ and @ weeks .